Hmdb loader
Record Information
Version5.0
StatusExpected but not Quantified
Creation Date2012-09-06 15:16:49 UTC
Update Date2022-03-07 02:51:40 UTC
HMDB IDHMDB0014563
Secondary Accession Numbers
  • HMDB14563
Metabolite Identification
Common NameMiglustat
DescriptionMiglustat is a drug used to treat Gaucher disease. It inhibits the enzyme glucosylceramide synthase, an essential enzyme for the synthesis of most glycosphingolipids. It is only used for patients who cannot be treated with enzyme replacement therapy with imiglucerase. It is marketed under the trade name Zavesca. Miglustat is now the first and only approved therapy for patients with Niemann-Pick disease type C (NP-C). It has recently been approved for treatment of progressive neurological symptoms in adult and pediatric patients in the European Union, Brazil, and South Korea.
Structure
Data?1582753193
Synonyms
ValueSource
BuDNJChEBI
ButyldeoxynojirimycinChEBI
MiglustatumChEBI
N-(N-Butyl)deoxynojirimycinChEBI
N-Butyl deoxynojirimycinChEBI
N-Butyl-1-deoxynojirimycinChEBI
N-ButylmoranolineChEBI
NB-DNJChEBI
SC-48334ChEBI
ZavescaChEBI
BrazavesKegg
N-(N-Butyl)deoxy-nojirimycinHMDB
N-ButyldeoxynojirimycinHMDB
OGT 918HMDB
Chemical FormulaC10H21NO4
Average Molecular Weight219.278
Monoisotopic Molecular Weight219.147058165
IUPAC Name(2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
Traditional Namemiglustat
CAS Registry Number72599-27-0
SMILES
CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
InChI Identifier
InChI=1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1
InChI KeyUQRORFVVSGFNRO-UTINFBMNSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as piperidines. Piperidines are compounds containing a piperidine ring, which is a saturated aliphatic six-member ring with one nitrogen atom and five carbon atoms.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPiperidines
Sub ClassNot Available
Direct ParentPiperidines
Alternative Parents
Substituents
  • Piperidine
  • 1,2-aminoalcohol
  • Secondary alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Polyol
  • Azacycle
  • Organic nitrogen compound
  • Hydrocarbon derivative
  • Primary alcohol
  • Organopnictogen compound
  • Organic oxygen compound
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External Descriptors
Ontology
Physiological effectNot Available
Disposition
ProcessNot Available
RoleNot Available
Physical Properties
StateSolid
Experimental Molecular Properties
PropertyValueReference
Melting Point169 - 172 °CNot Available
Boiling PointNot AvailableNot Available
Water Solubility331 g/LNot Available
LogP-0.6Not Available
Experimental Chromatographic PropertiesNot Available
Predicted Molecular Properties
PropertyValueSource
Water Solubility331 g/LALOGPS
logP-1.1ALOGPS
logP-1.2ChemAxon
logS0.18ALOGPS
pKa (Strongest Acidic)12.9ChemAxon
pKa (Strongest Basic)8.49ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area84.16 ŲChemAxon
Rotatable Bond Count4ChemAxon
Refractivity55.74 m³·mol⁻¹ChemAxon
Polarizability23.99 ųChemAxon
Number of Rings1ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DarkChem[M+H]+152.86131661259
DarkChem[M-H]-147.4831661259
DeepCCS[M+H]+155.73830932474
DeepCCS[M-H]-153.3830932474
DeepCCS[M-2H]-186.46830932474
DeepCCS[M+Na]+161.84130932474
AllCCS[M+H]+152.532859911
AllCCS[M+H-H2O]+148.732859911
AllCCS[M+NH4]+155.932859911
AllCCS[M+Na]+156.932859911
AllCCS[M-H]-151.432859911
AllCCS[M+Na-2H]-152.132859911
AllCCS[M+HCOO]-153.032859911

Predicted Retention Times

Underivatized

Chromatographic MethodRetention TimeReference
Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022.1.28 minutes32390414
Predicted by Siyang on May 30, 202210.1415 minutes33406817
Predicted by Siyang using ReTip algorithm on June 8, 20226.1 minutes32390414
AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid349.0 seconds40023050
Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid503.5 seconds40023050
Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid249.4 seconds40023050
Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid55.6 seconds40023050
Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid171.5 seconds40023050
RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid61.3 seconds40023050
Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid325.6 seconds40023050
BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid264.4 seconds40023050
HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate)798.4 seconds40023050
UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid612.4 seconds40023050
BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid44.8 seconds40023050
UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid712.1 seconds40023050
SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid167.6 seconds40023050
RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid223.8 seconds40023050
MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate766.3 seconds40023050
KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA519.6 seconds40023050
Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water325.5 seconds40023050

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
MiglustatCCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO3314.8Standard polar33892256
MiglustatCCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO1904.5Standard non polar33892256
MiglustatCCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO2070.0Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Miglustat,1TMS,isomer #1CCCCN1C[C@H](O[Si](C)(C)C)[C@@H](O)[C@H](O)[C@H]1CO1729.1Semi standard non polar33892256
Miglustat,1TMS,isomer #2CCCCN1C[C@H](O)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]1CO1713.2Semi standard non polar33892256
Miglustat,1TMS,isomer #3CCCCN1C[C@H](O)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]1CO1725.3Semi standard non polar33892256
Miglustat,1TMS,isomer #4CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO[Si](C)(C)C1760.7Semi standard non polar33892256
Miglustat,2TMS,isomer #1CCCCN1C[C@H](O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]1CO1763.1Semi standard non polar33892256
Miglustat,2TMS,isomer #2CCCCN1C[C@H](O[Si](C)(C)C)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]1CO1781.6Semi standard non polar33892256
Miglustat,2TMS,isomer #3CCCCN1C[C@H](O[Si](C)(C)C)[C@@H](O)[C@H](O)[C@H]1CO[Si](C)(C)C1803.8Semi standard non polar33892256
Miglustat,2TMS,isomer #4CCCCN1C[C@H](O)[C@@H](O[Si](C)(C)C)[C@H](O[Si](C)(C)C)[C@H]1CO1792.3Semi standard non polar33892256
Miglustat,2TMS,isomer #5CCCCN1C[C@H](O)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]1CO[Si](C)(C)C1817.7Semi standard non polar33892256
Miglustat,2TMS,isomer #6CCCCN1C[C@H](O)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]1CO[Si](C)(C)C1813.0Semi standard non polar33892256
Miglustat,3TMS,isomer #1CCCCN1C[C@H](O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H](O[Si](C)(C)C)[C@H]1CO1845.4Semi standard non polar33892256
Miglustat,3TMS,isomer #2CCCCN1C[C@H](O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]1CO[Si](C)(C)C1874.8Semi standard non polar33892256
Miglustat,3TMS,isomer #3CCCCN1C[C@H](O[Si](C)(C)C)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]1CO[Si](C)(C)C1901.7Semi standard non polar33892256
Miglustat,3TMS,isomer #4CCCCN1C[C@H](O)[C@@H](O[Si](C)(C)C)[C@H](O[Si](C)(C)C)[C@H]1CO[Si](C)(C)C1903.2Semi standard non polar33892256
Miglustat,4TMS,isomer #1CCCCN1C[C@H](O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H](O[Si](C)(C)C)[C@H]1CO[Si](C)(C)C1948.0Semi standard non polar33892256
Miglustat,1TBDMS,isomer #1CCCCN1C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H](O)[C@H]1CO1985.1Semi standard non polar33892256
Miglustat,1TBDMS,isomer #2CCCCN1C[C@H](O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)[C@H]1CO1961.9Semi standard non polar33892256
Miglustat,1TBDMS,isomer #3CCCCN1C[C@H](O)[C@@H](O)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1CO1976.4Semi standard non polar33892256
Miglustat,1TBDMS,isomer #4CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO[Si](C)(C)C(C)(C)C2011.8Semi standard non polar33892256
Miglustat,2TBDMS,isomer #1CCCCN1C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)[C@H]1CO2268.2Semi standard non polar33892256
Miglustat,2TBDMS,isomer #2CCCCN1C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1CO2277.7Semi standard non polar33892256
Miglustat,2TBDMS,isomer #3CCCCN1C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H](O)[C@H]1CO[Si](C)(C)C(C)(C)C2305.8Semi standard non polar33892256
Miglustat,2TBDMS,isomer #4CCCCN1C[C@H](O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1CO2277.8Semi standard non polar33892256
Miglustat,2TBDMS,isomer #5CCCCN1C[C@H](O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)[C@H]1CO[Si](C)(C)C(C)(C)C2307.0Semi standard non polar33892256
Miglustat,2TBDMS,isomer #6CCCCN1C[C@H](O)[C@@H](O)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1CO[Si](C)(C)C(C)(C)C2295.3Semi standard non polar33892256
Miglustat,3TBDMS,isomer #1CCCCN1C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1CO2553.4Semi standard non polar33892256
Miglustat,3TBDMS,isomer #2CCCCN1C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)[C@H]1CO[Si](C)(C)C(C)(C)C2582.1Semi standard non polar33892256
Miglustat,3TBDMS,isomer #3CCCCN1C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1CO[Si](C)(C)C(C)(C)C2601.5Semi standard non polar33892256
Miglustat,3TBDMS,isomer #4CCCCN1C[C@H](O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1CO[Si](C)(C)C(C)(C)C2595.6Semi standard non polar33892256
Miglustat,4TBDMS,isomer #1CCCCN1C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1CO[Si](C)(C)C(C)(C)C2835.9Semi standard non polar33892256
Spectra
Biological Properties
Cellular Locations
  • Membrane
Biospecimen Locations
  • Blood
  • Urine
Tissue LocationsNot Available
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB00419 details
UrineExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB00419 details
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDDB00419
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider ID46764
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkMiglustat
METLIN IDNot Available
PubChem Compound51634
PDB IDNot Available
ChEBI ID50381
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Moyses C: Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):955-60. [PubMed:12803929 ]
  2. Weinreb NJ, Barranger JA, Charrow J, Grabowski GA, Mankin HJ, Mistry P: Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol. 2005 Nov;80(3):223-9. [PubMed:16247743 ]
  3. Wraith JE, Imrie J: New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat. Ther Clin Risk Manag. 2009;5:877-87. Epub 2009 Nov 18. [PubMed:19956552 ]
  4. McCormack PL, Goa KL: Miglustat. Drugs. 2003;63(22):2427-34; discussion 2435-6. [PubMed:14609352 ]
  5. Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE: Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 2007 Sep;6(9):765-72. [PubMed:17689147 ]
  6. van Giersbergen PL, Dingemanse J: Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase. J Clin Pharmacol. 2007 Oct;47(10):1277-82. Epub 2007 Aug 24. [PubMed:17720777 ]

Enzymes

General function:
Cell wall/membrane/envelope biogenesis
Specific function:
Catalyzes the first glycosylation step in glycosphingolipid biosynthesis, the transfer of glucose to ceramide. May also serve as a "flippase".
Gene Name:
UGCG
Uniprot ID:
Q16739
Molecular weight:
44853.255
References
  1. Moyses C: Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):955-60. [PubMed:12803929 ]
  2. Weinreb NJ, Barranger JA, Charrow J, Grabowski GA, Mankin HJ, Mistry P: Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol. 2005 Nov;80(3):223-9. [PubMed:16247743 ]
  3. Chien YH, Lee NC, Tsai LK, Huang AC, Peng SF, Chen SJ, Hwu WL: Treatment of Niemann-Pick disease type C in two children with miglustat: initial responses and maintenance of effects over 1 year. J Inherit Metab Dis. 2007 Oct;30(5):826. Epub 2007 Jun 21. [PubMed:17603755 ]
  4. Treiber A, Morand O, Clozel M: The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat. Xenobiotica. 2007 Mar;37(3):298-314. [PubMed:17624027 ]
  5. Ficicioglu C: Review of miglustat for clinical management in Gaucher disease type 1. Ther Clin Risk Manag. 2008 Apr;4(2):425-31. [PubMed:18728838 ]
  6. Wraith JE, Imrie J: New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat. Ther Clin Risk Manag. 2009;5:877-87. Epub 2009 Nov 18. [PubMed:19956552 ]
  7. Pastores GM: Miglustat: substrate reduction therapy for lysosomal storage disorders associated with primary central nervous system involvement. Recent Pat CNS Drug Discov. 2006 Jan;1(1):77-82. [PubMed:18221193 ]
  8. McCormack PL, Goa KL: Miglustat. Drugs. 2003;63(22):2427-34; discussion 2435-6. [PubMed:14609352 ]
  9. Giraldo P, Latre P, Alfonso P, Acedo A, Alonso D, Barez A, Corrales A, Franco R, Roldan V, Serrano S, Pocovi M: Short-term effect of miglustat in every day clinical use in treatment-naive or previously treated patients with type 1 Gaucher's disease. Haematologica. 2006 May;91(5):703-6. Epub 2006 Apr 19. [PubMed:16627252 ]
  10. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]